China Universal Asset Management Co. Ltd. Acquires 14,497 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

China Universal Asset Management Co. Ltd. raised its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 52.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,234 shares of the biotechnology company’s stock after acquiring an additional 14,497 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Arrowhead Pharmaceuticals were worth $1,457,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in ARWR. Virtus Advisers LLC purchased a new stake in Arrowhead Pharmaceuticals during the 2nd quarter worth about $34,000. Salomon & Ludwin LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the third quarter valued at about $34,000. Nisa Investment Advisors LLC increased its position in shares of Arrowhead Pharmaceuticals by 75.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,308 shares during the period. Federated Hermes Inc. purchased a new stake in shares of Arrowhead Pharmaceuticals in the third quarter worth about $52,000. Finally, Smartleaf Asset Management LLC boosted its position in shares of Arrowhead Pharmaceuticals by 2,186.5% in the third quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,618 shares during the period. 62.61% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 10th. The Goldman Sachs Group boosted their price target on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, January 7th. Weiss Ratings upgraded Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, February 6th. Royal Bank Of Canada boosted their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. Finally, Piper Sandler restated an “overweight” rating and issued a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $81.67.

Arrowhead Pharmaceuticals Stock Down 0.4%

ARWR opened at $63.59 on Friday. The business’s fifty day simple moving average is $66.47 and its 200 day simple moving average is $46.72. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $76.76. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29. The stock has a market cap of $8.90 billion, a PE ratio of 41.56 and a beta of 1.21.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.38). The firm had revenue of $264.03 million for the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The company’s revenue for the quarter was up 10461.3% on a year-over-year basis. During the same period last year, the firm earned ($1.39) EPS. As a group, research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Adeoye Y. Olukotun sold 10,000 shares of the stock in a transaction on Friday, December 19th. The shares were sold at an average price of $67.66, for a total transaction of $676,600.00. Following the transaction, the director owned 33,600 shares of the company’s stock, valued at approximately $2,273,376. This trade represents a 22.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mauro Ferrari sold 7,530 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, December 26th. The stock was sold at an average price of $70.00, for a total transaction of $527,100.00. Following the completion of the transaction, the director owned 69,053 shares in the company, valued at approximately $4,833,710. The trade was a 9.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 510,836 shares of company stock valued at $33,603,060 over the last 90 days. Company insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.